Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06247488 · ClinicalTrials.gov registry record · Phase 4
Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users
A Phase 4 study, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
NCT06247488 is a Phase 4 study that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 110 participants.
The verdict
NCT06247488, a Phase 4 study, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the abuse potential of gabapentin enacarbil immediate release capsules taken alone and in combination with oxycodone in healthy adult, non-dependent, recreational opioid users.
Interventions
- DRUG Placebo
- DRUG Oxycodone 20 mg
- DRUG GE-IR 200 mg
- DRUG GE-IR 450 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2023-04-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06247488
The ClinicalTrials.gov registry entry for NCT06247488 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arbor Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06247488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06247488 about?
NCT06247488 is a clinical study titled "Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users". The purpose of this study is to assess the abuse potential of gabapentin enacarbil immediate release capsules taken alone and in combination with oxycodone in healthy adult, non-dependent, recreational opioid users.
What is the current status of trial NCT06247488?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2022-01-31. Estimated completion is 2023-04-25.
What interventions are being tested in trial NCT06247488?
The interventions under investigation include: Placebo (DRUG), Oxycodone 20 mg (DRUG), GE-IR 200 mg (DRUG), GE-IR 450 mg (DRUG).
Who is sponsoring clinical trial NCT06247488?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.